In Pudong, Baoshan, Minhang, Jinshan, Fengxian and other districts, the capacity of "Zhangjiang R&D + Shanghai Manufacturing" will be elevated to create future healthcare industry clusters.

Brain-computer interface. Breakthroughs in non-invasive brain-computer interface technology, brain-computer infusion technology, brain-like chip technology and neural models of brain computing will be accelerated. Basic research on brain engineering, brain neuroinformatics, artificial neural networks, among others, will be strengthened, and research and innovation in brain-like chips, brain-like micro and nano optoelectronic devices, brain-like computers, neural interfaces and intelligent prostheses will be advanced. Also, application of the brain-computer interface technology in such medical rehabilitation fields as physical movement disorders, chronic disorders of consciousness and mental diseases will be explored.

Biosafety. Significant advances will be made in key technologies such as new microorganisms, rapid pathogen identification, short-term scale detection and scientific traceability. Application of new vaccines, antibodies and molecules, immune diagnostics and other generic technology research and development will move ahead, major infectious disease prevention and control drugs with independent intellectual property rights will be developed, and a system of the biosafety industry established. In addition, support will be weighted towards the production and stockpiling of a number of major infectious disease prevention and control drugs, and testing reagents and equipment.

Synthetic biology. Breakthroughs in core underlying technology for DNA/RNA will be encouraged, and the automatic DNA/RNA synthesis systems based on bioinformatics and machine learning will be developed. A focus will be placed on the interactions between primary and secondary metabolism of organisms to develop generic cross-cutting technologies in metabolic science. Moreover, the commercialization of synthetic biotechnology in new drug development, medical and aesthetic medicine product development, microbial strain testing, biodegradable materials, etc. will be promoted.

Gene and cell therapy. Breakthroughs in technologies such as the accelerated delivery vector and gene editing will be made, and key technologies such as clinical-level viral vectors and large-scale cell culture processes will be encouraged. The development and commercialization of cell therapy, gene therapy, oncolytic virus and other related technology products will move faster. The innovation and industrial application of key raw materials, and important equipment and consumables will be supported.